A fluoroquinolone is described as having a C-8 methoxy group and C-7 bicyclic amine ring. These modifications PRIMARILY confer:

• A Expanded spectrum against MRSA through topoisomerase IV inhibition
• B Reduced CNS side effects by limited blood-brain barrier penetration
• C Enhanced activity against anaerobes and improved photostability ✓
• D Prolonged half-life by inhibiting CYP3A4-mediated metabolism

Explanation

The C-8 methoxy group in moxifloxacin enhances anaerobic activity and confers photostability (reducing phototoxicity seen with sparfloxacin's C-8 halogen). The bicyclic amine (azabicycle) at C-7 reduces P-glycoprotein efflux and improves activity against resistant strains. This combination makes moxifloxacin suitable for respiratory and intra-abdominal anaerobic coverage without the phototoxicity of earlier fluoroquinolones.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.